FGFR2 (C491A)

FGFR2 · Variant type: point · HGVS: p.C491A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pemigatinib	99.5%	0.5%	98.23
2	Infigratinib	99.3%	0.7%	98.24
3	Erdafitinib	97.8%	2.2%	95.71
4	Brigatinib	96.8%	3.2%	82.96
5	Selpercatinib	94.4%	5.6%	96.72
6	Ripretinib	92.7%	7.3%	92.95
7	Pazopanib	91.2%	8.8%	97.49
8	Deucravacitinib	89.5%	10.5%	98.99
9	Pralsetinib	85.7%	14.3%	93.43
10	Regorafenib	85.5%	14.5%	95.99
11	Vandetanib	80.5%	19.5%	95.74
12	Cabozantinib	79.5%	20.5%	92.73
13	Fostamatinib	73.8%	26.2%	96.74
14	Tivozanib	73.1%	26.9%	92.42
15	Repotrectinib	70.4%	29.6%	84.21
16	Entrectinib	67.2%	32.8%	93.69
17	Fedratinib	66.3%	33.7%	96.21
18	Futibatinib	62.7%	37.3%	98.48
19	Sunitinib	58.0%	42.0%	91.73
20	Tepotinib	57.4%	42.6%	99.75
21	Pirtobrutinib	53.0%	47.0%	99.49
22	Defactinib	48.3%	51.7%	92.68
23	Sorafenib	46.6%	53.4%	96.72
24	Pacritinib	46.4%	53.6%	88.64
25	Upadacitinib	44.9%	55.1%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pemigatinib	99.5%	98.7%	+0.8%
Infigratinib	99.3%	98.8%	+0.5%
Erdafitinib	97.8%	99.0%	-1.2%
Brigatinib	96.8%	96.1%	+0.7%
Selpercatinib	94.4%	95.0%	-0.6%
Ripretinib	92.7%	85.4%	+7.3%
Pazopanib	91.2%	88.9%	+2.3%
Deucravacitinib	89.5%	92.5%	-3.0%
Pralsetinib	85.7%	93.2%	-7.6%
Regorafenib	85.5%	—	—
Vandetanib	80.5%	90.8%	-10.3%
Cabozantinib	79.5%	—	—
Fostamatinib	73.8%	—	—
Tivozanib	73.1%	—	—
Repotrectinib	70.4%	79.8%	-9.4%
Entrectinib	67.2%	81.5%	-14.3%
Fedratinib	66.3%	—	—
Futibatinib	62.7%	99.3%	-36.6%
Sunitinib	58.0%	—	—
Tepotinib	57.4%	—	—
Pirtobrutinib	53.0%	—	—
Defactinib	48.3%	—	—
Sorafenib	46.6%	—	—
Pacritinib	46.4%	—	—
Upadacitinib	44.9%	—	—

Cancer	Organ	Source
endometrial_carcinoma	Uterus	ref
carcinoma_liver	Liver	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms